INmune Bio, Inc. (INMB) Misses Q3 EPS by 8c

INmune Bio, Inc. (NASDAQ: INMB) reported Q3 EPS of ($0.48), $0.08 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $43 thousand versus the consensus estimate of $46 thousand.

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)